België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gedeon richter plc - ethinylestradiol 0,02 mg; desogestrel 0,15 mg - filmomhulde tablet - 150 µg - 20 µg - desogestrel 0.15 mg; ethinylestradiol 0.02 mg - desogestrel and ethinylestradiol

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gedeon richter plc - ethinylestradiol 0,03 mg; desogestrel 0,15 mg - filmomhulde tablet - 150 µg - 30 µg - desogestrel 0.15 mg; ethinylestradiol 0.03 mg - desogestrel and ethinylestradiol

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fair-med healthcare gmbh - capecitabine 150 mg - filmomhulde tablet - 150 mg - capecitabine 150 mg - capecitabine

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fair-med healthcare gmbh - capecitabine 500 mg - filmomhulde tablet - 500 mg - capecitabine 500 mg - capecitabine

Europese Unie - Nederlands - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. het effect van imatinib op de uitkomst van beenmergtransplantatie is niet vastgesteld. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. de ervaring met imatinib bij patiënten met mds/mpd geassocieerd met pdgfr gen re-regelingen is zeer beperkt. er zijn geen gecontroleerde studies tonen een klinisch voordeel of een toegenomen overleving voor deze ziekten.

Europese Unie - Nederlands - EMA (European Medicines Agency)

actavis group ptc ehf. - memantine - ziekte van alzheimer - psychoanaleptics, andere anti-dementie drugs - behandeling van patiënten met matige tot ernstige ziekte van alzheimer.

Europese Unie - Nederlands - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - maagneoplasma - antineoplastische middelen - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Europese Unie - Nederlands - EMA (European Medicines Agency)

actavis group ptc ehf - reteplase - myocardinfarct - antitrombotische middelen - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

accord healthcare b.v. winthontlaan 200 3526 kv utrecht - anastrozol 1 mg/stuk - filmomhulde tablet - hypromellose (e 464) ; lactose 1-water ; macrogol 300 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; povidon k 30 (e 1201) ; titaandioxide (e 171), hypromellose (e 464) ; lactose 1-water ; macrogol 300 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; povidon k 30 (e 1201) ; titaandioxide (e 171), - anastrozole

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

actavis group ptc ehf - temozolomide; - capsule, hard - temozolomide